PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.
Rashid Sayyid and Zachary Klaassen preview six high-impact GU oncology abstracts upcoming at ESMO 2025 that could redefine treatment standards. Highlights include the KEYNOTE-905/EV-303 trial offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback